Similarly, combining TLR4/NF-κB and Nrf2-ARE pathway modulation offers a comprehensive approach to managing IBD by simultaneously reducing inflammation and enhancing antioxidant defenses. The gene discussed is TLR4; the disease is irritable bowel syndrome.